AFTER THE BELL: Backsliding in your weight-loss battle? There’s a judge to blame for that (opens original article in a new tab)

A South African court temporarily blocked iDexis from producing generic versions of weight-loss drugs Wegovy and Ozempic, citing unregistered active ingredients and unsafe manufacturing conditions, while the company claims it provides essential medicine access.

• High Court in Tshwane granted interim ruling against iDexis for producing generic versions of Wegovy and Ozempic
• iDexis sells 85,000 medication pens monthly, more than Novo Nordisk and Aspen in South Africa
• Sahpra found iDexis manufacturing drugs in unsafe conditions and active ingredients not registered with SA Health Products Regulatory Authority
• Novo Nordisk and iDexis may face further legal battles in Constitutional Court
• iDexis MD argues for access to safe medicine over commercial interests